Literature DB >> 29934200

Myotonic dystrophy type 1: reasons to be OPTIMISTIC.

Cynthia Gagnon1, Benjamin Gallais2, Luc Laberge3.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29934200     DOI： 10.1016/S1474-4422(18)30240-0

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  3 in total

1.  Interventions for promoting physical activity in people with neuromuscular disease.

Authors:  Katherine Jones; Fiona Hawke; Jane Newman; James Al Miller; Joshua Burns; Djordje G Jakovljevic; Grainne Gorman; Douglass M Turnbull; Gita Ramdharry
Journal:  Cochrane Database Syst Rev       Date:  2021-05-24

2.  MBNL1 reverses the proliferation defect of skeletal muscle satellite cells in myotonic dystrophy type 1 by inhibiting autophagy via the mTOR pathway.

Authors:  Kai-Yi Song; Xiu-Ming Guo; Hui-Qi Wang; Lei Zhang; Si-Yuan Huang; Ying-Chao Huo; Gang Zhang; Jin-Zhou Feng; Rong-Rong Zhang; Yue Ma; Qing-Zhe Hu; Xin-Yue Qin
Journal:  Cell Death Dis       Date:  2020-07-18       Impact factor: 8.469

3.  Quality of life and subjective symptom impact in Japanese patients with myotonic dystrophy type 1.

Authors:  Haruo Fujino; Toshio Saito; Masanori P Takahashi; Hiroto Takada; Takahiro Nakayama; Osamu Imura; Tsuyoshi Matsumura
Journal:  BMC Neurol       Date:  2022-02-14       Impact factor: 2.474
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.